checkAd

ViCapsys Life Sciences Appoints Three New Board Members

Mr. Richard Rosenblum, Dr. Colleen Delaney, and Mr. Charles Farrahar Appointed to the Board of DirectorsBring a Combined 75 Years of Financial and Pharmaceutical ExpertiseSUWANEE, GA / ACCESSWIRE / September 29, 2022 / ViCapsys Life Sciences, Inc., …

Mr. Richard Rosenblum, Dr. Colleen Delaney, and Mr. Charles Farrahar Appointed to the Board of Directors

Bring a Combined 75 Years of Financial and Pharmaceutical Expertise

SUWANEE, GA / ACCESSWIRE / September 29, 2022 / ViCapsys Life Sciences, Inc., (OTC PINK:VICP) ("ViCapsys" or the "Company"), today announced the appointment of Mr. Richard Rosenblum, Dr. Colleen Delaney, and Mr. Charles Farrahar to the Company's Board of Directors, effective September 22, 2022. In conjunction with these additions, Dr. John Potts and Mr. Michael Yurkowsky will be resigning from the Board of Directors. Dr. Potts will remain a board observer and advisor to ViCapsys.

"I am very pleased to announce the addition of Richard, Colleen, and Charles to the ViCapsys Board of Directors," said Federico Pier, Executive Chairman and Chief Executive Officer of ViCapsys. "The trio brings significant financial and pharmaceutical experience that will be complementary to our existing board. Their insights will be critical to leading our organization at this transformational time. We would also like to extend our appreciation to Dr. John Potts and Michael Yurkowsky, who will be resigning from the Board of Directors after serving the Company for eight and three years, respectively. I want to thank them for their dedication to ViCapsys."

Mr. Rosenblum, Dr. Delaney, and Mr. Farrahar jointly added, "This is a pivotal time for ViCapsys as the Company looks to accelerate its strategic plan to achieve beneficial therapies for patients around the world by leveraging natural pathways in a localized manner. ViCapsys' proprietary CXCL12 technology will position the Company to improve conditions for patients in a broad range of therapeutic areas as this technology has multiple applications. ViCapsys is currently focused on curing Type I diabetes, and we look forward to collaborating with management and other members of the board to support this mission."

Mr. Richard Rosenblum is Innovative Payment Solutions Inc.'s President, Chief Financial Officer, and Director, and has served in these roles since July 22, 2021. Mr. Rosenblum has served on the Board of H-Cyte since February 1, 2022. Since its founding in 1994, Richard has served as Chief Executive Officer and Principal at Harborview Capital Advisors LLC which provides strategic advisory services in the areas of capital formation, merchant banking and management consulting. Mr. Rosenblum is the owner of Harborview Property Management where he invests and manages domestic and international commercial real-estate, and multi-family real-estate assets. From 2008 to 2014, Mr. Rosenblum was a Director, President, and Executive Chairman of Alliqua Biomedical Inc. which developed and marketed hydrogel manufacturing technology in the wound care sector. His philanthropic and community-centered activities include being a founding board member of the Dr. David Feit Memorial Foundation (DFM), which for over 15 years raised money for the benefit and support of youth activities. Since 2018, Mr. Rosenblum has served on the Board of Directors of the Chilton Hospital Foundation. Mr. Rosenblum graduated Summa Cum Laude from SUNY Buffalo with a B.A. in Finance & Accounting.

Seite 1 von 3




0 Kommentare
Nachrichtenquelle: Accesswire
 |  126   |   |   

Schreibe Deinen Kommentar

Disclaimer

ViCapsys Life Sciences Appoints Three New Board Members Mr. Richard Rosenblum, Dr. Colleen Delaney, and Mr. Charles Farrahar Appointed to the Board of DirectorsBring a Combined 75 Years of Financial and Pharmaceutical ExpertiseSUWANEE, GA / ACCESSWIRE / September 29, 2022 / ViCapsys Life Sciences, Inc., …

Nachrichten des Autors

62 Leser
55 Leser
43 Leser
40 Leser
33 Leser
31 Leser
30 Leser
29 Leser
28 Leser
28 Leser
229 Leser
175 Leser
127 Leser
119 Leser
118 Leser
118 Leser
117 Leser
117 Leser
115 Leser
110 Leser
1234 Leser
821 Leser
461 Leser
372 Leser
332 Leser
308 Leser
275 Leser
244 Leser
243 Leser
229 Leser
4528 Leser
1731 Leser
1234 Leser
1125 Leser
942 Leser
906 Leser
897 Leser
821 Leser
766 Leser
658 Leser